<p>RIA Advisory Group LLC 在最近向證券交易委員會（SEC）披露的信息中表示，在第四季度將其在 Kodiak Sciences Inc.（NASDAQ:KOD - 免費報告）的持股減少了 31.9%。該機構投資者在此期間出售了 53,061 股後，持有該公司 113,473 股股票。Kodiak Sciences 大約佔 RIA Advisory Group LLC 持有的資產的 0.8%，使其成為該公司第 24 大持股。截止最近報告期末，RIA Advisory Group LLC 持有的 Kodiak Sciences 價值約為 3,173,000 美元，佔其總資產的約 0.21%。</p>
<p>獲取 <strong>Kodiak Sciences</strong> 警報：</p>
<p>其他機構投資者也對該公司的持股進行了調整。GF Fund Management CO. LTD. 在第四季度購買了 Kodiak Sciences 的新股份，價值約為 29,000 美元。Mirae Asset Global Investments Co. Ltd. 在第四季度購買了 Kodiak Sciences 的新股份，價值約為 72,000 美元。Strs Ohio 在第四季度收購了 Kodiak Sciences 的新股份，價值約為 87,000 美元。BNP Paribas Financial Markets 在第三季度將其在 Kodiak Sciences 的持股增加了 89.4%。BNP Paribas Financial Markets 目前持有該公司 6,373 股股票，價值 104,000 美元，此前在此期間又購買了 3,009 股。最後，Diversified Trust Co. 在第四季度收購了 Kodiak Sciences 的新股份，價值約為 219,000 美元。89.06% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Kodiak Sciences 股票表現</h2>
<p>KOD 股票在週五開盤價為 43.96 美元。該股票的市值為 27.3 億美元，市盈率為 -10.18，貝塔值為 2.32。該公司有 50 日簡單移動平均線為 33.92 美元，200 日簡單移動平均線為 26.88 美元。Kodiak Sciences Inc. 的 52 周最低價為 2.81 美元，52 周最高價為 47.84 美元。</p>
<p>Kodiak Sciences（NASDAQ:KOD - 獲取免費報告）最近於 3 月 31 日（星期二）發佈了其財報。該公司報告每股收益（EPS）為 -1.04 美元，低於分析師一致預期的 -1.02 美元，差距為 -0.02 美元。賣方分析師預測 Kodiak Sciences Inc. 在當前年度將發佈 -3.65 的每股收益。</p>
<h2>分析師評級調整</h2>
<p>KOD 曾是多份研究報告的主題。瑞銀集團在 3 月 27 日的報告中將 Kodiak Sciences 的目標股價從 50.00 美元上調至 80.00 美元，並給予該股票 &#34;買入&#34; 評級。HC Wainwright 在 3 月 27 日的報告中重申了 &#34;買入&#34; 評級，並將 Kodiak Sciences 的目標股價設定為 58.00 美元（上調自 38.00 美元）。最後，Weiss Ratings 在 1 月 22 日的報告中重申了對 Kodiak Sciences 的 &#34;賣出（e+）&#34; 評級。五位股票研究分析師對該股票給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，Kodiak Sciences 目前的平均評級為 &#34;適度買入&#34;，平均目標價格為 35.43 美元。</p>
<p><strong>閲讀我們關於 KOD 的最新股票報告</strong></p>
<h2>Kodiak Sciences 公司簡介</h2>
<p>（免費報告）</p>
<p>Kodiak Sciences, Inc 是一家總部位於加利福尼亞州帕洛阿爾託的臨牀階段生物製藥公司，專注於發現和開發治療視網膜疾病的新療法。該公司的專有技術集中在抗體生物聚合物結合物（ABCs）上，旨在延長耐久性、增強組織滲透性並改善現有治療方式的安全性。Kodiak 的研發工作針對濕性年齡相關性黃斑變性（濕性 AMD）、糖尿病性黃斑水腫（DME）和其他嚴重的眼科疾病。</p>
<p>Kodiak 管道中的主要產品候選是 KSI-301，一種通過玻璃體內注射給藥的抗 VEGF 抗體生物聚合物結合物。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票超過 Kodiak Sciences</li>
</ul>
<p><strong>想看看其他對沖基金持有哪些 KOD 嗎？</strong> 訪問 HoldingsChannel.com 獲取 Kodiak Sciences Inc.（NASDAQ:KOD - 免費報告）的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S09E?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S09E"/></p>
<p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Kodiak Sciences 嗎？</h2>
<p>在考慮 Kodiak Sciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買... 而 Kodiak Sciences 並不在名單上。</p>
<p>雖然 Kodiak Sciences 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

<p>RIA Advisory Group LLC 在第四季度減少了對 Kodiak Sciences Inc. (NASDAQ:KOD) 的持股比例，下降了 31.9%，目前持有 113,473 股。其他機構投資者也調整了他們的持倉，其中 GF Fund Management 和 Mirae Asset Global Investments 有顯著的新投資。Kodiak Sciences 的股票開盤價為 43.96 美元，市值為 27.3 億美元。該公司報告了上一季度每股虧損 1.04 美元，未能達到預期。分析師的評級各不相同，平均目標價為 35.43 美元，評級為 “適度買入”</p>

<p>RIA Advisory Group LLC reduced its position in Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 31.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 113,473 shares of the company's stock after selling 53,061 shares during the period. Kodiak Sciences comprises approximately 0.8% of RIA Advisory Group LLC's holdings, making the stock its 24th largest position. RIA Advisory Group LLC owned approximately 0.21% of Kodiak Sciences worth $3,173,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>RIA Advisory Group LLC 在最近向證券交易委員會（SEC）披露的信息中表示，在第四季度將其在 Kodiak Sciences Inc.（NASDAQ:KOD - 免費報告）的持股減少了 31.9%。該機構投資者在此期間出售了 53,061 股後，持有該公司 113,473 股股票。Kodiak Sciences 大約佔 RIA Advisory Group LLC 持有的資產的 0.8%，使其成為該公司第 24 大持股。截止最近報告期末，RIA Advisory Group LLC 持有的 Kodiak Sciences 價值約為 3,173,000 美元，佔其總資產的約 0.21%。</p>
</div><p>Get <strong>Kodiak Sciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Kodiak Sciences</strong> 警報：</p>
</div><p>Other institutional investors have also made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new position in shares of Kodiak Sciences in the fourth quarter worth approximately $29,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Kodiak Sciences in the fourth quarter worth approximately $72,000. Strs Ohio acquired a new stake in shares of Kodiak Sciences during the fourth quarter worth approximately $87,000. BNP Paribas Financial Markets boosted its holdings in shares of Kodiak Sciences by 89.4% during the third quarter. BNP Paribas Financial Markets now owns 6,373 shares of the company's stock worth $104,000 after purchasing an additional 3,009 shares during the period. Finally, Diversified Trust Co. acquired a new stake in shares of Kodiak Sciences during the fourth quarter worth approximately $219,000. 89.06% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他機構投資者也對該公司的持股進行了調整。GF Fund Management CO. LTD. 在第四季度購買了 Kodiak Sciences 的新股份，價值約為 29,000 美元。Mirae Asset Global Investments Co. Ltd. 在第四季度購買了 Kodiak Sciences 的新股份，價值約為 72,000 美元。Strs Ohio 在第四季度收購了 Kodiak Sciences 的新股份，價值約為 87,000 美元。BNP Paribas Financial Markets 在第三季度將其在 Kodiak Sciences 的持股增加了 89.4%。BNP Paribas Financial Markets 目前持有該公司 6,373 股股票，價值 104,000 美元，此前在此期間又購買了 3,009 股。最後，Diversified Trust Co. 在第四季度收購了 Kodiak Sciences 的新股份，價值約為 219,000 美元。89.06% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Kodiak Sciences Stock Performance</h2>
<div class="lb-trans"><h2>Kodiak Sciences 股票表現</h2>
</div><p>KOD stock opened at $43.96 on Friday. The stock has a market cap of $2.73 billion, a P/E ratio of -10.18 and a beta of 2.32. The firm has a 50 day simple moving average of $33.92 and a 200 day simple moving average of $26.88. Kodiak Sciences Inc. has a 52 week low of $2.81 and a 52 week high of $47.84.</p>
<div class="lb-trans"><p>KOD 股票在週五開盤價為 43.96 美元。該股票的市值為 27.3 億美元，市盈率為 -10.18，貝塔值為 2.32。該公司有 50 日簡單移動平均線為 33.92 美元，200 日簡單移動平均線為 26.88 美元。Kodiak Sciences Inc. 的 52 周最低價為 2.81 美元，52 周最高價為 47.84 美元。</p>
</div><p>Kodiak Sciences (NASDAQ:KOD - Get Free Report) last posted its earnings results on Tuesday, March 31st. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). Sell-side analysts predict that Kodiak Sciences Inc. will post -3.65 EPS for the current year.</p>
<div class="lb-trans"><p>Kodiak Sciences（NASDAQ:KOD - 獲取免費報告）最近於 3 月 31 日（星期二）發佈了其財報。該公司報告每股收益（EPS）為 -1.04 美元，低於分析師一致預期的 -1.02 美元，差距為 -0.02 美元。賣方分析師預測 Kodiak Sciences Inc. 在當前年度將發佈 -3.65 的每股收益。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>KOD has been the subject of several research reports. UBS Group raised their price target on shares of Kodiak Sciences from $50.00 to $80.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, March 27th. HC Wainwright restated a &#34;buy&#34; rating and set a $58.00 price target (up from $38.00) on shares of Kodiak Sciences in a report on Friday, March 27th. Finally, Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Kodiak Sciences in a report on Thursday, January 22nd. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Kodiak Sciences currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $35.43.</p>
<div class="lb-trans"><p>KOD 曾是多份研究報告的主題。瑞銀集團在 3 月 27 日的報告中將 Kodiak Sciences 的目標股價從 50.00 美元上調至 80.00 美元，並給予該股票 &#34;買入&#34; 評級。HC Wainwright 在 3 月 27 日的報告中重申了 &#34;買入&#34; 評級，並將 Kodiak Sciences 的目標股價設定為 58.00 美元（上調自 38.00 美元）。最後，Weiss Ratings 在 1 月 22 日的報告中重申了對 Kodiak Sciences 的 &#34;賣出（e+）&#34; 評級。五位股票研究分析師對該股票給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，Kodiak Sciences 目前的平均評級為 &#34;適度買入&#34;，平均目標價格為 35.43 美元。</p>
</div><p><strong>Read Our Latest Stock Report on KOD</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 KOD 的最新股票報告</strong></p>
</div><h2>Kodiak Sciences Profile</h2>
<div class="lb-trans"><h2>Kodiak Sciences 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company's proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak's research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.</p>
<div class="lb-trans"><p>Kodiak Sciences, Inc 是一家總部位於加利福尼亞州帕洛阿爾託的臨牀階段生物製藥公司，專注於發現和開發治療視網膜疾病的新療法。該公司的專有技術集中在抗體生物聚合物結合物（ABCs）上，旨在延長耐久性、增強組織滲透性並改善現有治療方式的安全性。Kodiak 的研發工作針對濕性年齡相關性黃斑變性（濕性 AMD）、糖尿病性黃斑水腫（DME）和其他嚴重的眼科疾病。</p>
</div><p>The lead product candidate in Kodiak's pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.</p>
<div class="lb-trans"><p>Kodiak 管道中的主要產品候選是 KSI-301，一種通過玻璃體內注射給藥的抗 VEGF 抗體生物聚合物結合物。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Kodiak Sciences</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Kodiak Sciences</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding KOD?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kodiak Sciences Inc. (NASDAQ:KOD - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有哪些 KOD 嗎？</strong> 訪問 HoldingsChannel.com 獲取 Kodiak Sciences Inc.（NASDAQ:KOD - 免費報告）的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S09E" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=KOD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kodiak Sciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Kodiak Sciences 嗎？</h2>
</div><p>Before you consider Kodiak Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Kodiak Sciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買... 而 Kodiak Sciences 並不在名單上。</p>
</div><p>While Kodiak Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Kodiak Sciences 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

RIA Advisory Group LLC 減少了對 Kodiak Sciences Inc. $KOD 的股票持有量